Loading…
Age Management Institute Santa Barbara, a compounding pharmacy, was cited for producing adulterated sterile drug products for intravenous therapy under insanitary conditions that violated federal manufacturing standards. During a March-April 2021 inspection, the FDA found the facility lacked a certified ISO 5 classified area required for sterile compounding and maintained aseptic processing areas that were difficult to clean and visibly dirty, putting patients at risk of contamination. The company voluntarily ceased production of IV drug products following the inspection and responded to the FDA's Form 483 observations.